Ascletis-B (01672) announced that it intends to exercise the general mandate granted by shareholders at the annual general meeting held on May 22, 2025, authorizing the board of directors to repurchase company shares. The company plans to repurchase shares in the open market at appropriate times. Under the repurchase mandate, the company is authorized to buy back up to 96.2846 million shares, representing 10% of the total issued shares (excluding treasury shares) as of the date of the annual general meeting.

On September 29, 2025, the board of directors decided to exercise the repurchase mandate and will purchase shares in the open market from time to time based on market conditions, using up to HK$300 million in funds (allocated from the company's internal financial resources) for the proposed share repurchase.

The company's current financial position is sound. The board believes that the current trading price of the shares does not reflect their intrinsic value. The board is confident that the proposed share repurchase can enhance the value of the shares, thereby improving returns for company shareholders.

Furthermore, the board believes that the proposed share repurchase reflects the company's confidence in its long-term business prospects and growth potential, and will ultimately benefit the company and serve the best interests of the company and its shareholders as a whole.